Cargando…

Reply: Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'

Detalles Bibliográficos
Autores principales:	Schirripa, M, Loupakis, F, Pollina, L, Cremolini, C, Pasquini, G, Falcone, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Reply to Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859939/ https://www.ncbi.nlm.nih.gov/pubmed/24157829 http://dx.doi.org/10.1038/bjc.2013.652

Ejemplares similares

Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab
por: Loupakis, F, et al.
Publicado: (2013)

Comment on ‘Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab'
por: Bibeau, F, et al.
Publicado: (2013)

Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2011)

FOLFOXIRI plus bevacizumab in the treatment of metastatic colorectal cancer patients with unresectable liver metastases
por: Antoniotti, Carlotta, et al.
Publicado: (2022)

Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial
por: Suenaga, Mitsukuni, et al.
Publicado: (2020)

Reply to comment on: “Advantages of bevacizumab for aggressive posterior retinopathy of prematurity”
por: Schechet, Sidney A., et al.
Publicado: (2019)

Reply to the Comment of G. Feulner
por: Weber, Werner
Publicado: (2011)

Reply to the Comment by Littlechild and Isupov
por: Willetts, Andrew, et al.
Publicado: (2017)

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2017)

Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors
por: Sunakawa, Yu, et al.
Publicado: (2018)

Reply to “Missing Skeletal Muscle Metastases of Papillary Thyroid Carcinoma”
por: Hitu, Liviu, et al.
Publicado: (2020)

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
por: Cremolini, Chiara, et al.
Publicado: (2018)

In Reply to: Comments on Behavior of Healthcare Workers After Injuries From Sharp Instruments
por: Adib-Hajbaghery, Mohsen, et al.
Publicado: (2014)

A Reply to “Comments on “A New Elliptical Model for Device-Free Localization””
por: Lei, Qian, et al.
Publicado: (2018)

Reply to the Comments from Readers
por: Wang, Min, et al.
Publicado: (2018)

Reply: “Comment on: Endogenous Ouabain and Related Genes in the Translation from Hypertension to Renal Diseases”
por: Simonini, Marco, et al.
Publicado: (2019)

Reply to the Comment Re: Magalhães-Sant’Ana, M. Animals 2019, 9, 168
por: Magalhães-Sant’Ana, Manuel
Publicado: (2020)

Reply to “Comment on ‘Glass Transition, Crystallization of Glass-Forming Melts, and Entropy”’ by Zanotto and Mauro
por: Schmelzer, Jürn W. P., et al.
Publicado: (2018)

Reply to Comment on “Enumeration of Escherichia coli in Probiotic Products. Microorganisms 2019, 7, 437”
por: Zimmer, Camille, et al.
Publicado: (2020)

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
por: Antoniotti, Carlotta, et al.
Publicado: (2020)

Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
por: Loupakis, Fotios, et al.
Publicado: (2013)

Reply to “Comment on: Effects of Nigella Sativa on Type-2 Diabetes Mellitus: A Systematic Review”
por: Hamdan, Amiza, et al.
Publicado: (2020)

Reply to Comment by Young et al.
por: Mathews, F., et al.
Publicado: (2009)

Reply from Authors to the Editorial Comment
por: Kiss, Bernhard, et al.
Publicado: (2016)

Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review
por: Walter, H, et al.
Publicado: (2013)

Reply to Dhawan et al. Comment on “Kim et al. The Association between Coffee Consumption and Risk of Colorectal Cancer in a Korean Population. Nutrients 2021, 13, 2753”
por: Kim, Youngyo, et al.
Publicado: (2021)

Reply to the Comment on: Marco Cirillo The Memory of the Heart. J. Cardiovasc. Dev. Dis. 2018, 5, 55
por: Cirillo, Marco
Publicado: (2018)

Reply to Comment on Re-Visiting Immunogenicity Associated with Botulinum Toxin Treatment. Toxins 2019, 11, 491
por: Bellows, Steven, et al.
Publicado: (2020)

Reply to “Comment on the Correlation between Complete Blood Count Parameters and Appendix Diameter for the Diagnosis of Acute Appendicitis”
por: Daldal, Emin, et al.
Publicado: (2020)

Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO
por: Rossini, D., et al.
Publicado: (2021)

Reply to “Comment on Casiraghi et al. ‘Mucoadhesive Budesonide Formulation for the Treatment of Eosinophilic Esophagitis’ 2020, 12, 211”
por: Casiraghi, Antonella, et al.
Publicado: (2020)

Reply to Comments: A Lightweight and Low-Power UAV-Borne Ground Penetrating Radar Design for Landmine Detection
por: Šipoš, Danijel, et al.
Publicado: (2020)

Reply to comment on: Urinary sodium excretion and its association with blood pressure in Nigeria: A nationwide population survey
por: Odili, Augustine N., et al.
Publicado: (2021)

Reply to: “Comment on the Role of Muscle Mass Gain Following Protein Supplementation Plus Exercise Therapy in Older Adults with Sarcopenia and Frailty Risks: A Systematic Review and Meta-Regression Analysis of Randomized Trials, Nutrients 2019, 11, 1713”
por: Liao, Chun-De, et al.
Publicado: (2019)

Reply to Comment on “Environmental and Occupational Risk Factors of Amyotrophic Lateral Sclerosis: A Population-Based Case-Control Study”
por: Filippini, Tommaso, et al.
Publicado: (2020)

Reply to Comment “Assessing Porous Media Permeability in Non-Darcy Flow: A Re-Evaluation Based on the Forchheimer Equation”
por: Castro, A. P. G., et al.
Publicado: (2020)

Reply to Comments: Using the Cardio-Ankle Vascular Index (CAVI) or the Mathematical Correction Form (CAVI(0)) in Clinical Practice
por: Spronck, Bart, et al.
Publicado: (2020)

Reply to Comments on “Shiga-Toxin Producing Escherichia coli in Brazil: A Systematic Review. Microorganisms 2019, 7, 137”
por: Castro, Vinicius Silva, et al.
Publicado: (2019)

Reply to Najjar, R.S. Comment on “Dyńka et al. The Ketogenic Diet and Cardiovascular Diseases. Nutrients 2023, 15, 3368”
por: Dyńka, Damian, et al.
Publicado: (2023)

Reply to Comment on Detection of Mycotoxin in Patients with Chronic Fatigue Syndrome. Toxins 2013, 5, 605-617 by Mark J. Mendell †
por: Brewer, Joseph, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8793ag3b5n5ia0742argh2g85d